Lulizumab pegol
Monoclonal antibody
- none
- 1421830-13-8
- 8460
- none
- LCT264LTYE
Lulizumab pegol (INN;[1] development code BMS-931699) is a monoclonal antibody designed for the treatment of autoimmune diseases.[2]
This drug was developed by Bristol-Myers Squibb.
References
- v
- t
- e
Monoclonal antibodies for the immune system
Human | |
---|---|
Humanized | |
Veterinary |
Mouse |
|
---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e